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ABSTRACT: Nanoparticles (NPs) made of metals, polymers, micelles, and
liposomes are increasingly being used in various biomedical applications. However,
most of these NPs are hazardous for long- and short-term use and hence have
restricted biomedical applications. Therefore, naturally derived, biocompatible, and
biodegradable nanoconstructs are being explored for such applications. Inspired by
the biology of viruses, researchers are exploring the viral proteins that hold
considerable promise in biomedical applications. The viral proteins are highly stable
and further amenable to suit specific biological applications. Among various viral
proteins, vesicular stomatitis virus glycoprotein (VSV-G) has emerged as one of the
most versatile platforms for biomedical applications. Starting with their first major
use in lentivirus/retrovirus packaging systems, the VSV-G-based reagents have been
tested for diverse biomedical use, many of which are at various stages of clinical
trials. This manuscript discusses the recent advancements in the use of the VSV-Gbased reagents in medical, biological research, and clinical applications particularly
highlighting emerging applications in biomedical imaging.

1. INTRODUCTION
Vesicular stomatitis virus (VSV) is an enveloped virus that
belongs to the Rhabdoviridae family. Vulnerable hosts for VSV
include cattle, horses, and pigs. The negative-sense singlestranded RNA genome of the virus encodes for five proteins
found in the gene order: nucleoprotein (N), phosphoprotein
(P), matrix protein (M), glycoprotein (G), and large protein
(L)1 (Figure 1). The simplicity of its genomic organization and
the ease of growing the virus to high titers in most mammalian
cells have propelled VSV as a workhorse for the understanding
of myriad aspects of cellular and viral processes. The VSV
glycoprotein VSV-G is the determinant for viral attachment
and entry into susceptible host cells. The VSV-G contains
∼500 amino acids and is post-translationally modified with Nlinked glycosylation and fatty acid addition. In the matured
virion, the protein remains in trimeric and fusogenic form. This
form of the protein enables viral attachment to the host cell
receptors and promotes virus entry via a clathrin-mediated
endocytic mechanism. Continued research in molecular
virology, viral protein structure, host responses to viral
infections and viral pathogenesis, etc. has resulted in a detailed
understanding of the biochemical and biophysical properties of
VSV-G protein and its associated functions. Additionally, the
ease of production, purification, and customization processes
has made the VSV-G-based platform an attractive tool for
various biomedical applications.
© 2022 The Authors. Published by
American Chemical Society

Figure 1. Schematic of wild-type VSV and VSV-G-based nanocarrier.
The bullet-shaped VSV genome encodes five proteins: polymerase
(L), nucleoprotein (N), phosphoprotein (P), matrix protein (M), and
glycoprotein (G). It serves as a platform for bioengineering from
VSV-G for different biological applications.
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Although VSV has been exploited to understand many
important aspects of cellular, molecular, and viral processes,
two unique aspects of the biology of VSV have led to
significant advances in studies on many other viruses. The early
observations that VSV incorporating the envelope proteins of
other viruses can be readily generated from cells coinfected
with the viruses 2 firmly established the concept of
“pseudotypes” proposed previously.3 With the ability to
manipulate the VSV genome to generate recombinant viruses
lacking the viral G protein, pseudotype VSVs incorporating
envelope proteins of different families of viruses have been
generated in recent years. These studies have led to better
understanding of the entry mechanisms of viruses, identifying
receptors, generating live viral vaccine vectors, developing
virus-neutralization tests, and identifying neutralizing antibodies, as well as developing pseudotype viruses for studies under
low-containment facilities for viruses that otherwise require
high-containment facilities. Additionally, the use of VSV-G
protein in pseudotyping to generate stable, high titers of
lentiviral vectors with broad cell tropism4 has revolutionized
the field of gene and cell therapy.
The other unique aspect of VSV-G protein is its ability to
generate virus-like particles (VLPs) when ectopically expressed
in a variety of eukaryotic cells. These VLPs contain the viral G
protein on the envelope and can incorporate cytoplasmic
contents of cells from which these VLPs are produced. These
properties have been exploited to produce VLPs that can
package proteins, therapeutic molecules, large macromolecular
complexes such as CRISPR-Cas9 ribonucleoprotein complexes, and naked DNA.5 In addition, VSV-G has been
modified to target to specific cell types. Interestingly, when
VSV-G protein was expressed from an autonomously
replicating viral replicon lacking the viral structural proteins,
the G protein packaged the replicon and generated novel
infectious particles that could be propagated in cultured cells.6
Overall, these studies point to the importance of VSV-G for its
use in diverse areas of biomedical research and applications. In
this manuscript, we highlight the recent development of VSVG platforms and their biomedical applications, particularly
emphasizing its potential for biomedical imaging.
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apparatus in an inactive form to the cell surface where it exists
in an active fusogenic form.15 The crystal structures of both
pre-and post-fusion postfusion forms of VSV-G have been
resolved.17 The protein’s monomer is made up of four distinct
domains. Domain I of the VSV-G is dense with β sheets,
whereas domain II is centrally located and involved in protein
trimerization. Domain IV is the fusogenic domain that was
discovered to be inserted into the loop of the pleckstrin
homology domain III.13 VSV-G binds to host cell receptors
such as low-density lipoprotein (LDL) and its family members.
During binding with the host cell receptor, the protein
undergoes significant rearrangement and mediates membrane
fusion. VSV-G remains as a trimer in the mature virion at pH 7
in the prefusion state.14 The large changes in the protein’s
orientation are caused by the secondary structure, a hinge
region found between the pleckstrin homology domains and
the fusion domain. This rearrangement causes the protein to
transition from the prefusion to the postfusion state. The
conformational transition in VSV-G caused by low pH allows
the viral and endosomal membranes to fuse, resulting in the
release of the viral genome into the cytosol where the
ribonucleoprotein complex initiates transcription and subsequent translation of viral proteins including VSV-G. The
nascent protein is cotranslationally inserted into membranes of
the endoplasmic reticulum (ER). The ectodomain of VSV-G
undergoes post-translational modifications (PTM) in the form
of N-glycosylation at two asparagine residues. Following PTM,
the VSV-G forms microdomains at the plasma membrane that
serve as sites for virion assembly and budding. The reversible
pH-dependent conformational changes with fusogenic properties and signature sequences in its various domains make VSVG a unique molecular tool for researchers.

3. BIOMEDICAL APPLICATIONS OF THE VSV-G
3.1. Development of the VSV-G VLPs. Viruses are
naturally evolved nanocarriers. They efficiently transport their
genomes to specific host cells. Because a virus is an obligate
intracellular parasite, carrying the genome to the host cell is
quintessential for its replication. Most viruses have a lipid
membrane (envelope) derived from the host cell; however,
some viruses are nonenveloped, with no membrane but only
the proteinaceous capsid. While protecting the genome, the
capsids or envelopes have the ability for conformational
changes to unlock and swiftly transfer the genome to the
permissible cells. The viral envelope typically consists of a lipid
bilayer with transmembrane glycoproteins embedded in it. In
the case of VSV and many other negative-sense (NS) RNA
virus infections, mainly three forms of particles are produced in
the infected cells. In the majority of cases, the budding
particles carrying a full-length copy of the viral genome are
mature infectious virions. Another form, namely, defective
interfering (DI) particles, have a truncated genome package.
These defective genomes have packaging signal sequences
but are deficient for self-replication as they do not contain the
necessary genes expressing viral polymerase functions.
However, these particles are structurally homologous to the
parent virus but need a helper virus for their genome
replication. The third category of particles is completely
empty in nature; these are self-assembled protein cage-like
structures lacking nucleic acid in their core. These are also
structural homologues of the parent virus and are often termed
virus-like particles or VLPs. The nature of protein-protein
interactions dictates the assembling of the viral protein

2. STRUCTURE AND FUNCTION OF VSV-G
VSV-G is a type I transmembrane protein folded into a
structure with a short carboxy-terminal cytoplasmic tail and
transmembrane domain and an amino-terminal ectodomain
representing the bulk of the protein. It exists in a dynamic
equilibrium between monomeric and trimeric forms both on
the viral envelope and in infected cells; however, the
biologically active form of the protein is considered to be
trimeric.7 The cytoplasmic domain of VSV-G interacts with the
M protein for efficient virus assembly, although modifications
of this domain including deletions and replacements with those
from other viral and nonviral sequences can lead to viral
assembly. The ectodomain is responsible for binding to the
host cell receptor and subsequent fusion with the endosomal
membrane for the uncoating of the viral genome. It also
contains antibody recognition sites as well as viral neutralizing
epitopes.
VSV-G is a class III fusion protein8 that is characterized by
its pH-dependent reversible conformational changes between
pre- and postfusion states.9−12 This pH-dependent reversible
conformational transition is thought to be critical for its
intracellular transport in acidic compartments of the Golgi
32841
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Table 1. Biomedical Applications of VSV-G VLPs
tools
plasmid-based gene therapy
viral vector pseudotypes
delivery of mRNA
delivery of CRISPR-Cas9
selective delivery of protein
and nucleic acids
exogenous protein delivery

short description

in vivo/in
vitro

coexpression of VSV-G and IL-12 for gene therapy

in vitro and
in vivo
flaviviruses, coronaviruses, paramyxoviruses, herpes simplex virus, and other lentiviral vectors are the gold standard; in vivo
however, VSV-G lentivirus has been shown to be effective
VSV-G VLPs as mRNA-delivery vehicle
in vitro
VSV-G-based envelope carrier
in vivo
VSV-G-established VLPs as a delivery vehicle
in vitro
protein transduction method based on VSV-G-based nanovesicles

cancer immunotherapy

VSV-G expresses macrophages acting as fusogenic cells to deliver the GOI

functionalization of drugdelivery vectors

layer-by-layer (LbL) microcarrier surface functionalized by VSV-G to enhance cellular uptake

in vitro and
in vivo
in vitro and
in vivo
in vivo

Figure 2. Schematic representation of step-up and step-down approaches for the production, purification, and cargo loading in a VSV-G
nanocarrier. Step-up approach: in this process, the gene of a viral structural protein is cloned in an expression vector for protein production on a
large scale. However, the step-down approach begins with using the parent virus by depleting its genetic material. In the end, the protein is
collected as particles with no infectious properties. The downstream process of purification, such as clarification, purification, and polishing, is used
to obtain the purified protein.

lipid-bound fusogenic nanovesicles. Several molecular tools
based on VSV-G are successfully utilized for clinical research
and aptly used to package biological materials, including smallmolecule drugs, protein, peptides, DNA, mRNA, etc., as shown
in Table 1. Like the parent virions, these VSV-G-derived
carrier nanoparticles (NPs) undergo the same pathway for
their attachment and internalization. During endocytosis, the
conventional NP formulation encounters lysosomal hydrolase,
resulting in the degradation of most of the delivery agents. On
the other hand, the VSV-G-encapsulated formulation confers
endolysosomal escape to deliver cargo into the cytoplasm of
target cells. Besides these, VSV-G VLPs have excellent
biophysical properties that enable their use at the forefront
as a nanocarrier. These include stable morphology, well-known
surface properties, ease of large production, a higher surface
area-to-mass ratio, and the ability to encapsulate small
molecules.
Additionally, VSV-G particles are often compatible with a
wide variety of active pharmacological moieties. Because a

subunits that form the VLPs. These structures naturally remain
hollow inside and therefore can carry specific cargo volumes.
Like the parent virion, VLPs could be either enveloped or just
have a proteinaceous capsid layer.
As mentioned earlier, the VSV-G protein has the natural
ability to assemble into VLPs when expressed in cells.
Investigators have optimized the production of VLPs based
on recombinant expression of G in numerous cell types and
functionalized these for various biological and medical
applications. As the VSV glycoprotein’s structural transitions
are reversible, this property has allowed researchers to
introduce a package-specific volume of cargo/small molecules
into the VLPs, resulting in useful reagents. On the basis of
these principles, VSV-G-expressing cell lines are extensively
used as a packaging system for the production of important
biological reagents such as gene delivery platforms, geneediting tools, mRNAs, etc.
When expressed in human or mammalian cells, VSV-G selfassembles and is released at a very high titer in the form of
32842
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membrane. Often, eukaryotic cells pose additional challenges
in the form of host restriction factors that interfere with virus
release, which is an innate mechanism to limit viral spread.
However, VSV-G can antagonize interferon (IFN)-inducible
antiviral host cell factor tetherin (BST-2, CD317) and enhance
the release of VLPs. Thus, VSV-G can be produced in high
titer even in the presence of tetherin-expressing cells.15
3.2. Emergence of VSV-G as an Accessory Tool for
Gene Therapy. Due to its broad cell tropism, VSV-G
supports efficient gene transfer into a wide range of target cells
such as neurons, bone marrow stem cells (BMSCs), rat
insulinoma cell line INS-1, etc. For the past three decades,
VSV-G-based, pseudotyping platforms to package retroviral/
lentiviral vectors are being used for stable gene transfer in
eukaryotic cells.4 The emergence of a VSV-G-based retroviral/
lentiviral packaging platform made significant improvements
against murine leukemia virus-derived vectors in two major
aspects: (i) removal of the barrier of the restricted host-cell
range and (ii) production of high titer with uniformly
infectious particles. As a result, this platform revolutionized
gene therapy model studies in suitable animal hosts.
Subsequently, a plethora of basic research was completed
prior to any clinical trial studies for gene therapy. Progress in
this direction led to associated technology for surface
modification of VLPs in the form of maneuvering amino acid
residues or by tagging anchor moiety to enhance gene delivery
efficiency. Further, VSV-G can form complexes with plasmid
DNA, creating fusogenic structures. These complexes show
enhanced transfection properties for gene delivery without a
lipofection reagent.5 Interestingly, the engineering of the VSVG delivery system has been demonstrated to improve nucleic
acid transduction efficiency. The mRNA of a particular gene is
preferred because it is transient and does not pose any risk of
integration in target cells, so appropriate delivery systems are
being tested continuously. In this context, researchers have
demonstrated VSV-G-based chimeric viral particles for the
delivery and transduction of green fluorescence protein (GFP)
mRNA in monocytes and pluripotent stem cells (iPS cells).16
Similarly, targeted delivery of small VSV-G anchored
extracellular vesicles showed superior gene transduction
efficiency. Experiments conducted by Liu et al. demonstrated
that siRNA targeting programmed death-1 (PD-L1) can also
be efficiently administered in vivo in CT26 tumor-bearing mice
using a VSV-G-based system.17 This approach enabled robust
silencing of PDL-1 in tumor tissue, which in turn elevated
effector CD8+ T cell function, resulting in faster tumor
clearance. Because of these excellent examples, there is a
growing interest in gene delivery using the VSV-G-based
system for a variety of biomedical applications.
3.3. VSV-G-Encapsulated Nanoformulations for Biomedical Imaging. Biomedical imaging, mainly to detect the
early stages of cancer, is in high demand for timely therapeutic
intervention. Exogenously administered contrast agents are
routinely used for in vivo studies for mapping the contour of
the developing tumor. In this context, modified viruses are
being demonstrated for the delivery of exogenous contrast
agents to aid available imaging techniques such as positron−
electron tomography (PET), magnetic resonance imaging
(MRI), and optical imaging. The success of the technique rests
on surface modification with appropriate ligands such as metal
nanoparticles and contrast agents. The use of VSV-G-based
nanoparticles has recently been demonstrated as an improved
imaging carrier.18 Currently, fluorescence imaging has emerged

surface-exposed amino acid residue is amenable to further
modifications and tagging, these particles could therefore be
further modified with specific ligands and/or moieties for cell
receptor targeting and site-specific delivery of packaged
formulation. Hence, a smaller quantity of drugs is required
when administered through VLPs, eliminating overdose and
offsite target-related toxic effects. Often, this could result in
cost-effective treatment. Thus, with desired modifications,
these nanovesicles have been shown to transport eukaryotic
genes, mRNA, proteins, and organelles to different mammalian
cells and tissues. Because a VSV-G VLP is functionally active
like that of the parent virion, it has emerged as a potential
drug-delivery platform in recent years.
3.1.1. Methods of VSV-G VLP Production. VLPs are highly
organized, multiprotein hollow structures resembling that of a
natural virion. On the basis of the physical properties of the
parent virus, two significant modes are used for VLP
production: (i) in the step-down approach, the genome is
depleted from the parent virus and the VPLs are assembled,
and (ii) in the step-up approach, there is an expression of
required viral proteins in a suitable host and subsequent
assembly of VLPs (Figure 2). In the latter case, expressed viral
proteins self-assemble into particles. Various expression
systems, including prokaryotic, eukaryotic, and cell-free
systems, have been explored for VLP production. However, a
fair understanding of the viral structural components is
essential for the selection of an appropriate expression system.
The popular expression systems include bacteria, yeast, plant,
insect, and mammalian cells.
Although the bacterial system is the most commonly used
recombinant protein expression platform, several limiting
factors such as lack of or improper PTM, contamination of
endotoxins, incomplete disulfide-bond formation, and protein
solubility restrict the use of a bacterial expression system for
VLP production of enveloped viruses, including VSV-G.
Similarly, yeast expression systems, such as those of
Saccharomyces cerevisiae and Pichia pastoris, are not yet
optimized for VSV-G VLP production. Although genome
manipulation of these hosts has resulted in improved PTM of
the desired protein, issues like protein trafficking, proper
protein folding, etc. restrict the use of the yeast system for
VSV-G VLP expression.
The insect cell expression system is widely used for
generating viral proteins on laboratory and industrial scales.
The significant advantage of this system includes PTM of the
protein, like mammalian system capability of fast and largescale cultivations, high protein yield, etc. Typically, this system
utilizes recombinant baculovirus as a gene expression tool.
Here, the coexpression of multiple proteins by designing
polycistronic recombinant baculovirus can also be achieved.
However, the most commonly used system is the mammalian
cell expression system, where cell lines such as Chinese
hamster ovary (CHO) cells, baby hamster kidney-21 (BHK21), CEVEC’s amniocyte production cell line derived from
human amniocytes, human embryonic kidney 293T
(HEK293T), Vero cells, etc. are routinely used. However,
low protein yield, higher production cost, long-expression time,
and the possibility to carry infection with other pathogens such
as bacteria, fungi, or viruses are potential drawbacks of
mammalian cell expression systems for generating clinicalgrade VLPs. Apart from the suitability of the platform, one of
the important criteria for achieving a high titer VLP production
is the spontaneous release of VLPs from the mammalian cell
32843
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as an effective noninvasive technique for cancer diagnosis in
preclinical settings. However, it is difficult to look into the
human body beyond penetration depth (1 mm) using visible
radiation. However, biological tissues are transparent in the
near-infrared (NIR) range; thus, deeply buried inhomogeneity
can be observed by NIR imaging. NIR imaging offers the
advantage of minimal autofluorescence and enhanced tissuepenetration depth (5−10 mm).19 Also, the inclusions of
exogenous contrast agents in the NIR spectrum offer an
improved signal-to-noise ratio and a better contrast for easy
diagnosis. In this context, we recently demonstrated that
fabricated NIR-active VSV-G VLPs encapsulating indocyanine
green (ICG) dye, a U.S. Food and Drug Administration
(FDA) approved contrast agent, could be used in routine
biomedical imaging. Here VSV-G VLPs were generated in the
mammalian expression system (HEK 293T cells) in the
secretory form and were purified from the conditioned media
using simple ultracentrifugation steps. These VLPs encapsulated ICG, which we termed NIR active viral nanoconstructs
(NAVNs). Compared to the free form of ICG, the VSV-G
packaged form not only enhanced the photostability of this
contrast agent but also significantly improved the targeted
delivery of the contrast agent into the cytoplasm. The NIR
imaging showed enhanced fluorescence intensity and improvement in the signal-to-noise ratio (SNR) of NAVN-treated cells
compared to free ICG. Even after 72 h of treatment with cells,
the encapsulated form was ∼60% optically active while the free
ICG activity fell below ∼20%.18 This approach also showed
dramatic improvement in the circulating half-life of ICG in
preclinical mouse model studies. The improved circulating
half-life of ICG was partly because of the stability of the
formulation in blood circulation aided by sustained release of
the drug from VLPs over time. In vivo experiments conducted
in BALB/c by our group demonstrated that free ICG was
almost eliminated from the circulation within 24 h of
administration, while encapsulated ICG remained beyond 72
h of administration (Figure 3). For this study, the NAVNs and
free ICG solution were administered intravenously via tail vein
in BALB/c mice. The free ICG was given at a dose of 3 mg/kg
of body weight. Fluorescence images were taken 24 and 48 h
after injection. These images were captured at an excitation
wavelength of 745 nm, emission wavelength of 840 nm, and
exposure time of 2−6 s. Histopathological examination of these
mice did not show any significant cytotoxicity effect when
administered with VSV-G VLPs, thus showing the biocompatibility of these particles in a preclinical setup. Therefore, as a
proof of concept, we demonstrate that bioengineered VSV-G
encapsulating ICG could be a superior NIR-imaging platform
and has the potential for immediate medical-imaging
applications.
3.3.1. Mechanistic Insight into VSV-G ICG Interaction. To
better understand the mechanism of ICG packaging, we
performed a molecular dynamics (MD) simulation to check
the interaction of ICG with VSV-G protein. MD simulations
are frequently preferred to investigate the structure and
dynamics of biomolecules and various time-dependent
dynamical processes. The MD simulation approach is wellestablished and suitable for elucidating the ligand-binding
function, predicting binding poses, and determining the
conformational dynamics of the binding pockets. Herein, we
looked at the interactions between ICG and VSV-G by
employing molecular docking and MD simulation in
conjunction with the free energy calculation. The dye molecule
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Figure 3. In vivo wholebody NIR imaging of the biodistribution of
free ICG and NAVNs injected intravenously in BALB/c mice. (a)
NIR fluorescence image of mice 24 h postinjection of ICG and
NAVNs. (b) NIR fluorescence image of mice 48 h postinjection of
ICG and NAVNs. (c) NIR fluorescence image of mice dissected 48 h
postinjection of NAVNs. The figure is part of the doctoral research
work carried out by Suman Bishnoi.

(ICG) was docked into the binding pocket of VSV-G (PDB:
5I2S) using the Schrödinger suite. The best pose from the
docking study was subjected to MD simulation in both neutral
and acidic (pH 5.0) aqueous solutions by performing
conventional molecular dynamics (cMD) and constant pH
molecular dynamics (CpHMD) using the AMBER18 suite. For
cMD, before the production run, two-step minimization
followed by a stepwise heating step was performed. In the
case of CpHMD, after every 200 fs of explicit MD simulation,
the protonation change event was attempted for all possible
residues in the GB implicit model. Details of our simulation
protocol can be found in our previous studies.20 In the current
study, we performed MD simulations for 100 ns in both the
neutral and acidic conditions, which stabilize after 55 ns, as
shown in Figure 4a.
We also investigated the stability of the ICG molecule in the
binding pocket by estimating the center of the mass distance of
the ligand and the binding site residues throughout the
simulation time (Figure 4b). In the case of the neutral
condition, ICG was found to remain tightly bound to the
binding pocket (Figure 4c). On the other hand, in the acidic
condition (pH 5), ICG deviated from its original binding site
and remained attached to the protein’s surface (Figure 4d).
This implies that, in the acidic environment, the ligand binding
is destabilized.
This analysis is further complemented by estimating the
binding free energy of the VSV-G/ICG complex using the
molecular mechanics/Poisson−Boltzmann surface area (MM/
32844
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Figure 4. MD simulations of the VSV-G/ICG complex in neutral (pH 7.0, red) and acidic (pH 5, green) conditions. (a) Time evolution of rootmean-squared deviation (RMSD) of backbone atoms of VSV-G. (b) Time evolution of the center of mass (CoM) distance between the protein and
ICG. (c) Superimposition of the initial conformation with the final structure obtained from MD simulation at pH 7.0. The initial and final
coordinates of ICG are depicted in blue and green. (d) Superimposition of the initial snapshot with the final structure obtained from the MD
simulation at pH 5, where the initial and final coordinates of ICG are in blue and green. (e) Various components of total binding free energy (kcal/
mol) of ICG in neutral and acidic conditions.

PBSA) scheme. The estimated binding free energy is −25.16
kcal/mol in the neutral solution, almost 6 times more favorable
than the acidic state (−4.41 kcal/mol). The binding affinity of
ICG in low pH decreased significantly due to the loss of
profitable contribution from the intermolecular van der Waals
and electrostatic interactions (Figure 4e). Overall, the binding
free energy calculations corroborate the center of mass
distance analysis.
Thus, the molecular dynamics simulation study showed that
VSV-G undergoes conformational changes in a low pH
environment and triggers the release of ICG to the cytoplasm
of the target cell. Further, the VSV-G−ICG interaction
enhanced the half-life of ICG in the cells, thereby improving
the physical and optical stability of the contrast agent. Thus,
VSV-G could further be customized and engineered by fusing
NIR fluorescent protein or an antibody for in vivo imaging.21
3.4. Therapeutic Agent Delivery. Pharmaceutical agents
can be encapsulated in a VSV-G nanocarrier to enhance
delivery potential; for example, the partially purified VSV-G in
the form of vesicles released from a transfected cell is
commonly used to encapsulate various therapeutic agents.
This system can encapsulate a diverse array of small molecules
including protein, RNA, siRNA, and ICG, including the
delivery of genome editing tools. In this context, the VSV-G
platform is explored for delivering the CRISPR-SpCas9ribonucleoprotein complexes (RNPs) to various transformed,
pluripotent stem cell cardiomyocytes in an in vivo model.22
VSV-G has also been demonstrated to package recombinant
proteins by cotransfection of VSV-G with Gag-GFP for direct
delivery into the cytoplasm of target cells.23 Furthermore, these
nanocarriers could efficiently incorporate proteins, such as
tetracycline repressor (TetR) trans activator and murine
cationic amino acid transporter-1 (mCAT-1), and the receptor
of murine leukemia virus (MLV) envelope to target cells.24
Thus, this method of protein transduction is a versatile tool for
the transport of various cytoplasmic, nuclear surface proteins
into the target cells.

4. SITE-DIRECTED MODIFICATION OF VSV-G FOR
ENHANCED DELIVERY
VSV-derived VLPs are structurally and functionally homologous to their parent virions. The crystal structure of VSV-G
provides detailed information related to various domains and
its associated functions, including protein-protein interaction
for multimerization, exposed residues for immune targeting,
binding and fusion loop for host cell receptors, etc. The crystal
structure further reveals the presence of a transmembrane
domain, which undergoes structural rearrangement in response
to low pH. Various modifications of VSV-G have been carried
out at the amino acid level to enhance the targeting and cargodelivery abilities of the nanoconstructs. Researchers have
identified that VSV-G has several feasible insertion sites
between amino acids 1 and 400, which could tolerate 9-amino
acid cyclin-RGD (cRGD) peptides. Insertion of 49-amino acid
echistatin (snake venom disintegrin) peptide binding between
amino acids 351 and 352 in the middle of the lateral domain of
VSV-G specifically targeted integrins expressed on the tumor
tissue.25 On the basis of this evidence, it is possible to
customize VSV-G with an appropriate modification of amino
acid sequences to improve tissue-specific targeting of these
nanocarriers. At the postproduction stage, these nanocarriers
can also be modified by insertion or chemical conjugation of
targeting moieties at the surface of the particles.16
Besides this, VSV-G bears a fusion-loop structure and a
hydrophobic part, potentially exposed to interact with host
cellular organelles. The structural analysis predicts the
possibility of modifying individual domains of VSV-G, keeping
its self-assembling ability intact. Previous studies have
confirmed that VSV-G can be genetically engineered for tissue
targeting by incorporating collagen-binding decapeptide NWREPGRMELN-C showing specific attachment with the
collagen matrix.26 Likewise, the single-chain antibody fragment
(scFv) of 253-amino acid peptide has also been successfully
incorporated within VSV-G for specific binding with MHC-I.27
All of these type of modifications make VSV-G an attractive
and amenable candidate for VLP generation.
32845
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5. IMMUNOGENICITY AND NEUROTOXICITY ISSUES
AND POSSIBLE MITIGATION STRATEGY
Despite significant research progress, the clinical application of
VSV-G platforms for drug delivery and biomedical imaging is
limited. This is primarily due to a strong humoral (B cell)
response against VSV-G protein. The protein has several
immunodominant epitopes, including the most potent one at
the C-terminal end of the protein. Thus, VSV-G VLPs can
induce a strong humoral immune response even after a single
dose of application. The host-neutralizing antibodies (IgG) are
primarily targeted at the G protein. This strong immunogenicity leads to serum inactivation of the VSV-G-based
nanocarrier, making this platform unsuitable for multiple
applications. Importantly, like other rhabdoviruses, VSV-G
could also elicit life-long memory T cell and B cell responses.
This is a major hindrance to multidose therapeutic applications
of VSV-G-derived reagents, including the VLPs mentioned
here. The other drawback associated with the VSV-G-based
application is the inherent neurotropism associated with G.28
Although this attribute could be exploited for broader organspecific applications, including delivery to the brain, adequate
modifications and amino acid alternations are desired for such
application. Unlike in a VSV-infected host, where G is
produced at a logarithmically higher scale associated with
virus replication, biomedical application of VLPs is limited in
quantity and scale and organ-specific. As a result, the chances
of neurotoxicity are minimized to tolerable limits. Deleting the
specific immunodominant epitope or alterations of a few
amino acids could thus avoid immunogenicity to a large extent.
Thus, the combination of epitope deletion and site-directed
mutagenesis could make an immune-tolerable G.29 Moreover,
the immunodominant region of VSV-G can be switched with
the serum-resistant glycoprotein protein of other viruses.30 We
hope that, with these strategies, both neurotoxicity and
immunogenicity issues could be addressed to a larger extent.
The other approach for addressing immunogenicity relies on
switching the glycoproteins from another serotype. VSV is
prevalent in two major serotypes, VSV Indiana (VSVI) and
VSV New Jersey (VSVNJ), having neutralizing antibody
responses that are not cross-reactive. These differential
immune response properties thus could be exploited for repeat
applications of a VSV-G-derived nanocarrier. Besides this
approach, the glycoprotein of other Vesiculoviruses, such as
the Chandipura virus (CHPV), could be explored in
combination with VSVI and VSVNJ for multiple in vivo
applications.

Mini-Review

biocompatibility, make this platform a valuable research tool.
As discussed, VSV-G nanocarriers can encapsulate many active
molecules; still, there is room for improvement. One major
drawback lies in the immune response to G protein, preventing
multiple applications in the same host. However, epitope
manipulation and change of serotypes are postulated to tackle
such issues. Finally, we anticipate that continued future
research in this direction would make the VSV-G platform a
viable option for biomedical applications in clinical settings.
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